Thomas Bachelot (T Bachelot)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 39

Top Venues

British journal of cancer

Nature medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Breast cancer (Tokyo, Japan)

Université Joseph Fourier (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Université Joseph Fourier

France

PHD

Publications

Helene Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul-Henri Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachelot
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer 130 (4) (2024)
Helene Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul-Henri Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachelot
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer 130 (4) (2024)
Marie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, Thomas Bachelot, Thomas Filleron, Ludovic Lacroix, Alicia Tran-Dien, Pascal Jézéquel, Marjorie Mauduit, Janice Barros Monteiro, Marta Jimenez, Stefan Michiels, Valery Attignon, Isabelle Soubeyran, Keltouma Driouch, Nicolas Servant, Christophe Le Tourneau, Maud Kamal, Fabrice Andre, Ivan Bièche
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British journal of cancer (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Helene Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul-Henri Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachelot
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer 130 (4) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Helene Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul-Henri Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachelot
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer 130 (4) (2024)
Helene Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul-Henri Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachelot
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer 130 (4) (2024)
Helene Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul-Henri Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachelot
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Helene Vanacker, Isabelle Treilleux, Camille Schiffler, Ivan Bieche, Mario Campone, Anne Patsouris, Monica Arnedos, Paul-Henri Cottu, Jean-Philippe Jacquin, Florence Dalenc, Antoine Pinton, Nicolas Servant, Valéry Attignon, Etienne Rouleau, Alain Morel, François Legrand, Marta Jimenez, Fabrice Andre, Thomas Bachelot
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British journal of cancer 130 (4) (2024)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) (2023)
Hélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Jean-Sébastien Frenel, Séverine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule Augereau, Thomas Bachelot, Lionel Uwer, Marc Debled, Jean-Marc Ferrero, Florian Clatot, Anthony Goncalves, Michael Chevrot, Sylvie Chabaud, Paul-Henri Cottu
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study. Cancers 15 (4) (2023)
Lajos Pusztai, Mariya Rozenblit, Peter Dubsky, Thomas Bachelot, Anna M Kirby, Barbro K Linderholm, Julia R White, Steven J Chmura, Lisa Anne Carey, Boon H Chua, Kathy D Miller
De Novo Oligometastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Fabiola Giudici, Barbara Pistilli, Ines Vaz-Luis, Maryam Karimi, Suzette Delaloge, Thomas Bachelot, Stefan Michiels, Aurelie Bardet
Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer. British journal of cancer (2023)
Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, Yoann Pradat, Agnes Ducoulombier, Barbara Pistilli, Thomas Bachelot, Frederic Viret, Christelle Levy, Nicolas Signolle, Alexia Alfaro, Diep T N Tran, Ingrid Judith Garberis, Hugues Talbot, Stergios Christodoulidis, Maria Vakalopoulou, Nathalie M Droin, Aurelie Stourm, Maki Kobayashi, Tomoya Kakegawa, Ludovic Lacroix, Patrick Saulnier, Bastien Job, Marc Deloger, Marta Jimenez, Thierry Petit, Vianney Baris, Pierre Laplante, Patricia L Kannouche, Virginie Marty, Magali Lacroix-Triki, Véronique Diéras, Fabrice Andre
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature medicine (2023)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Khalil Hodroj, David Pellegrin, Cindy Menard, Thomas Bachelot, Thierry Durand, Philippe Toussaint, Armelle Dufresne, Benoite Mery, Olivier Trédan, Thibaut Goulvent, Pierre Etienne Heudel
A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study. JMIR cancer 9 (2023)
Francois-Clement Bidard, Nicolas Kiavue, William Jacot, Thomas Bachelot, Sylvain Dureau, Hughes Bourgeois, Anthony Goncalves, Etienne G C Brain, Sylvain Ladoire, Florence Dalenc, Joseph Gligorov, Luis Teixeira, George Emile, Jean-Marc Ferrero, Delphine Loirat, Luc Cabel, Amir Kadi, Véronique Diéras, Catherine Alix-Panabières, Jean-Yves Pierga
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Khalil Hodroj, David Pellegrin, Cindy Menard, Thomas Bachelot, Thierry Durand, Philippe Toussaint, Armelle Dufresne, Benoite Mery, Olivier Trédan, Thibaut Goulvent, Pierre Etienne Heudel
A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study. JMIR cancer 9 (2023)
Hélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Jean-Sébastien Frenel, Séverine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule Augereau, Thomas Bachelot, Lionel Uwer, Marc Debled, Jean-Marc Ferrero, Florian Clatot, Anthony Goncalves, Michael Chevrot, Sylvie Chabaud, Paul-Henri Cottu
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study. Cancers 15 (4) (2023)
Jean-Sébastien Frenel, A Lusque, Suzette Delaloge, J-M Ferrero, Thomas Bachelot, I Desmoulins, C Levy, J-C Eymard, A Gonçalves, Anne Patsouris, M A Mouret Reynier, M J-C Thery, T Petit, Luc Cabel, L Uwer, M Debled, M Chevrot, A Mailliez, William Jacot, T de La Motte Rouge
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British journal of cancer (2023)
Hélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Jean-Sébastien Frenel, Séverine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule Augereau, Thomas Bachelot, Lionel Uwer, Marc Debled, Jean-Marc Ferrero, Florian Clatot, Anthony Goncalves, Michael Chevrot, Sylvie Chabaud, Paul-Henri Cottu
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study. Cancers 15 (4) (2023)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Thomas Bachelot, Gail S Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N Schwartz, Timothy J Pluard, Francesco Ricci, William R Gwin, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarína Petráková, Denise A Yardley, Orit Freedman, Erik H Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter Andreas Fasching, Peter A Kaufman, Emily J Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J Gradishar, null null
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Thomas Bachelot, Paul-Henri Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith M Bliss, Jean-Luc Canon, Frédérique M Penault-Llorca, Jérôme Lemonnier, David A Cameron, Fabrice Andre
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (32) (2022)
Elise Bonnet, Véronique Haddad, Stanislas Quesada, Kim-Arthur Baffert, Audrey Lardy-Cléaud, Isabelle Treilleux, Daniel Pissaloux, Valéry Attignon, Qing Wang, Adrien Buisson, Pierre-Etienne Heudel, Thomas Bachelot, Armelle Dufresne, Lauriane Eberst, Philippe Toussaint, Valérie Bonadona, Christine Lasset, Alain Viari, Emilie Sohier, Sandrine Paindavoine, Valérie Combaret, David Pérol, Isabelle L Ray-Coquard, Jean Yves Blay, Olivier Trédan
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial. Journal of personalized medicine 12 (10) (2022)
Lidia Delrieu, Marina Touillaud, Olivia Pérol, Magali Morelle, Agnès Martin, Christine M Friedenreich, Pauline Mury, Armelle Dufresne, Thomas Bachelot, Pierre Etienne Heudel, Beatrice Fervers, Olivier Trédan, Vincent Pialoux
Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer. Oxidative medicine and cellular longevity 2021 (2021)
Pauline Corbaux, Audrey Lardy-Cleaud, Marie Alexandre, Maxime Fontanilles, Christelle Lévy, Alessandro Adriano Viansone, Audrey Mailliez, Marc Debled, Anthony Goncalves, Fanny Le Du, Florence Lerebours, Jean-Marc Ferrero, Jean-Christophe Eymard, Marie-Ange Mouret-Reynier, Thierry Petit, Jean-Sébastien Frenel, Florence Dalenc, Coralie Courtinard, Marie Chaix, Thomas Bachelot
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer. Breast cancer research and treatment (2021)
Sara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U Lin, Melissa Bear, Sonya C Chapman, Zhengyu Yang, Yanyun Chen, Carey K Anders
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (20) (2020)
Caroline Bailleux, Lauriane Eberst, Thomas Bachelot
Treatment strategies for breast cancer brain metastases. British journal of cancer 124 (1) (2020)
Sara M Tolaney, Young-Hyuck Im, Emiliano Calvo, Yen-Shen Lu, Erika Hamilton, Andres Forero-Torres, Thomas Bachelot, Michela Maur, Angelica Fasolo, Ralph Tiedt, Lisa Nardi, Uz Stammberger, Ahmed M Abdelhady, Shiling Ruan, Soo Chin Lee
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (2) (2020)
Lidia Delrieu, Vincent Pialoux, Olivia Pérol, Magali Morelle, Agnès Martin, Christine M Friedenreich, Olivia Febvey-Combes, David Pérol, Elodie Belladame, Michel Clémençon, Eva Roitmann, Armelle Dufresne, Thomas Bachelot, Pierre Etienne Heudel, Marina Touillaud, Olivier Trédan, Beatrice Fervers
Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. JMIR mHealth and uHealth 8 (1) (2020)
Bojana Stefanovska, Cecile Edith Vicier, Thibault Dayris, Vasily Ogryzko, Veronique Scott, Ibrahim Bouakka, Suzette Delaloge, Anna Rocca, Olivier Trédan, Thomas Bachelot, Fabrice André, Olivia Fromigué
Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. Cancer research 80 (11) (2020)
Lidia Delrieu, Jeff K Vallance, Magali Morelle, Beatrice Fervers, Vincent Pialoux, Christine M Friedenreich, Armelle Dufresne, Thomas Bachelot, Pierre Etienne Heudel, Olivier Trédan, Olivia Pérol, Marina Touillaud
Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer. European journal of cancer care 29 (1) (2019)
Lidia Delrieu, Olivia Pérol, Beatrice Fervers, Christine M Friedenreich, Jeff K Vallance, Olivia Febvey-Combes, David Pérol, Brice Canada, Eva Roitmann, Armelle Dufresne, Thomas Bachelot, Pierre Etienne Heudel, Olivier Trédan, Marina Touillaud, Vincent Pialoux
A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial. JMIR research protocols 7 (8) (2018)

Thomas Bachelot.css-eqlu8i{font-size:small;padding-left:4px;} (T Bachelot)

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas Bachelot (T Bachelot)